Kevetrin activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis.Kevetrin has demonstrated potent anti-tumor efficacy against various carcinoma xenograft models: lung, breast, colon, prostate and squamous cell carcinoma, and in a leukemia tumor model. In drug-resistant cell lines, Kevetrin has shown excellent activity, galvanizing the Company to focus on Kevetrin's development potential in this area.
| Molecular Weight | 179.67 |
| Formula | C5H10ClN3S |
| CAS Number | 66592-89-0 |
| Solubility (25°C) | DMSO ≥ 30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related p53 Products |
|---|
| BAY 1892005
BAY 1892005, a p53 protein modulator, is active on p53 condensates and does not lead to mutant p53 reactivation. |
| FOXO4-DRI
FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53. |
| p53 (17-26)
p53 (17-26) is amino acids 17 to 26 fragment of p53. |
| Azurin p28 peptide
Azurin p28 peptide is a tumor-penetrated antitumor peptide. |
| INV-102
INV-102 is a p53 and Pax6 activator that can be used in studies related to dry eye. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
